Lecanemab decision marks first time patients can begin treatment with home administration
— Lecanemab decision marks first time patients can begin treatment with home administration
by Judy George, Deputy Managing Editor, MedPage Today
July 14, 2026
• 2 min read
The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik) to treat adults with Alzheimer's disease, the agency said Monday.
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows…
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according to a…
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
Das neue Alzheimer-Medikament Lecanemab kann den Verlauf der Krankheit im Frühstadium um einige Monate verzögern. Seit dem 1.…
